MAI Capital Management Decreases Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• MAI Capital Management has reduced its stake in Boston Scientific Corporation by 18.7%, owning 149,755 shares valued at approximately $15.1 million after selling 34,444 shares in the first quarter.
• Several large investors, including NS Partners Ltd and Bank Pictet & Cie Europe AG, have adjusted their positions in Boston Scientific, with NS Partners increasing its holdings by 1.6%.
• Boston Scientific reported better-than-expected earnings for the last quarter, with EPS of $0.75 compared to analysts' expectations of $0.72, and a year-over-year revenue increase of 22.8%.

MAI Capital Management decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 18.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 149,755 shares of the medical equipment provider's stock after selling 34,444 shares during the quarter. MAI Capital Management's holdings in Boston Scientific were worth $15,107,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Colonial Trust Co SC grew its stake in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at about $26,000. Y.D. More Investments Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $27,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of a number of recent research reports. Robert W. Baird boosted their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Oppenheimer boosted their price objective on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a research note on Thursday, July 24th. UBS Group boosted their price objective on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Leerink Partners initiated coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Finally, Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $117.50.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. This trade represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by company insiders.

Boston Scientific Price Performance

BSX stock traded up $0.72 during midday trading on Wednesday, hitting $107.38. The company's stock had a trading volume of 7,518,463 shares, compared to its average volume of 5,622,467. Boston Scientific Corporation has a 12 month low of $80.50 and a 12 month high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $159.10 billion, a price-to-earnings ratio of 63.91, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. The company has a 50 day moving average of $104.71 and a two-hundred day moving average of $102.18.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the prior year, the company posted $0.62 EPS. The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.